by GOT | Sep 20, 2021 | News
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as...
by GOT | Sep 7, 2021 | News
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit Company Contact: Koral Couch 781-935-8141 x119 FOR...
by GOT | Aug 24, 2021 | News
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc....
by GOT | Feb 8, 2021 | News
Azurity Pharmaceuticals Announces Three New Neurology Products WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care,...
by azur2019wp | Sep 11, 2019 | News
Azurity All-Hands Company Meeting WOBURN, Mass. (September 11, 2019) – This September two companies met and became one, Azurity Pharmaceuticals is the beginning of that new family. This was a time to meet and get to know each other and build as an organization....
by azur2019wp | Jul 10, 2019 | News
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for...
Recent Comments